After a whirlwind of conference news Monday, we're doing it all over again with Day 2 of the J.P. Morgan Healthcare ...

Less than four months after rejecting Sentynl Therapeutics and Cyprium Therapeutics’ treatment for Menkes disease, the FDA ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | Bristol Myers Squibb is already aiming ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

The FDA has issued a complete response letter for the partners’ application in EBV+PTLD, marking the agency’s second snub of ...

In a preliminary report of its 2025 results, Apellis said that sales of its geographic atrophy (GA) drug Syfovre came in at ...

Now, the Chicago-based pharma is heading southwest as it charts the next leg of its stateside investment tour.

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Mind Medicine has altered its state, rebranding as Definium Therapeutics ahead of a series of phase 3 data drops on its lead ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.